- Insurance rollout shows pharmacies and NACDS in action
- FDA approves liquid form of Merck HIV drug Isentress for infants, small children
- Axe aims for world peace with Axe Peace, campaign
- NACDS issues statement on White House health reform meeting
- NACDS supports bill to curb Rx abuse, safeguard patients
WHITEHOUSE STATION, N.J. — Merck has cleared a hurdle in its effort to buy eye care company Inspire Pharmaceuticals for $430 million, the company said Thursday.
The expiration of the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 brings Merck one step closer to acquiring Inspire.
Merck announced its intention to buy Raleigh, N.C.-based Inspire for $5 per share on April 15.